REG - Convatec Group PLC - Notice of AGM

ConvaTecAnnouncement

Today 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260317:nRSQ0035Xa&default-theme=true

RNS Number : 0035X  Convatec Group PLC  17 March 2026

17 March 2026

Convatec Group Plc

("Convatec" or "the Company")

Notice of Annual General Meeting

 

The Company's annual general meeting (the "Annual General Meeting") will take
place at 14:00 (UK time) on Thursday 21 May 2026 at the Company's offices at
20 Eastbourne Terrace, London W2 6LG.

The Company's Notice of Annual General Meeting and Form of Proxy including
details of how shareholders can appoint a proxy, are being sent to
shareholders today and have been submitted to the National Storage Mechanism
in accordance with UK Listing Rule 6.4.1 of the Financial Conduct Authority.
These documents will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

A copy of the Company's Notice of Annual General Meeting can be accessed on
the Company's website at www.convatecgroup.com (http://www.convatecgroup.com)
.

This announcement is made in accordance with DTR 6.3.5R(1A).

 

Enquiries

James Kerton, Company
Secretary
 

Email: cosec@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 3.1 Additional regulated information required to be disclosed
under the laws of the United Kingdom

 

 

About Convatec

 

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000
colleagues, we provide products and services in around 90 countries, united by
a promise to be forever caring. Our solutions provide a range of benefits,
from infection prevention, treatment for hard to heal wounds, at-risk skin and
ulcerated tissue to supporting debilitating conditions, improved patient
outcomes and reduced care costs. Convatec's revenues in 2025 were over $2
billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To
learn more please visit http://www.convatecgroup.com
(https://www.convatecgroup.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUBSURNRUOAAR



            Copyright 2019 Regulatory News Service, all rights reserved